In this issue:
- Can AI tackle key challenges in MS?
- Memory B cell-guided extended interval dosing of ocrelizumab
- The association of comorbidities with sleep quality among pwMS
- Management strategies for pwMS taking oral cladribine beyond year 4
- Patterns of DMT utilisation before, during, and after pregnancy
- Ocrelizumab vs interferon/ glatiramer acetate in people over age 60
- aHSCT vs natalizumab in progressive MS
- Clinical relapses and disease outcomes in pwMS older than 50
- Hypogammaglobulinaemia during rituximab treatment
- Medication adherence in MS patients with cognitive problems
Please login below to download this issue (PDF)